Novavax, a US biotech company, said on the 28th that the results of phase III clinical trials of its candidate new crown vaccine in the UK showed that the effectiveness of the vaccine exceeded 89%. At the same time, the effective rate of the vaccine against the new coronavirus variant found in the UK is more than 85%.
Fifteen thousand people participated in the clinical trial of Novavax, and 62 people were finally diagnosed with the new coronavirus, including 6 in the vaccination group and 56 in the control group (placebo), CNBC reported on the 28th. The effectiveness of the vaccine is estimated to be 89.3%.
The study also found that Novavax’s new crown vaccine had an effective rate of 85.6% against the mutated virus found in the UK. However, phase II trials in South Africa showed that the vaccine had limited effect on the mutated virus found in South Africa. The results showed that the effective rate of the vaccine was only 49.4% in 44 confirmed cases in South Africa. In these confirmed cases, about 90% of the cases are caused by the new coronavirus mutation.
In response to the situation in South Africa, novavaks said it plans to select an improved version of the vaccine in the next few days to better prevent the new variant virus, and it is expected to test the improved vaccine in the second quarter of this year.
According to the report, it is not clear whether the data released on the 28th will enable Novax to obtain an emergency use license from the US Food and Drug Administration (FDA) to allow it to be sold in the United States.